Basilea Pharmaceutica AG (OTCMKTS:BPMUF – Get Free Report) was the target of a significant drop in short interest in the month of May. As of May 15th, there was short interest totaling 546 shares, a drop of 88.1% from the April 30th total of 4,577 shares. Approximately 0.0% of the shares of the company are short sold. Based on an average trading volume of 0 shares, the days-to-cover ratio is presently ∞ days.
Basilea Pharmaceutica Stock Performance
Basilea Pharmaceutica stock opened at $65.10 on Thursday. The business’s 50 day simple moving average is $69.28 and its 200 day simple moving average is $67.49. The company has a current ratio of 5.11, a quick ratio of 4.68 and a debt-to-equity ratio of 0.59. Basilea Pharmaceutica has a 12 month low of $57.70 and a 12 month high of $74.00.
Basilea Pharmaceutica Company Profile
Basilea Pharmaceutica AG is a Swiss biopharmaceutical company headquartered in Basel, specializing in the development and commercialization of innovative treatments for hospital‐treated diseases. The company’s research is focused primarily on anti‐infectives and oncology, with a portfolio that spans both marketed products and early‐ to late‐stage pipeline candidates. Basilea leverages medicinal chemistry expertise to address critical medical needs in fungal infections, bacterial infections and cancer.
Among its lead products is isavuconazole, a broad‐spectrum antifungal agent marketed under the trade name Cresemba.
Read More
- Five stocks we like better than Basilea Pharmaceutica
- Abercrombie Rallies as Strong Q1 Earnings Extend Winning Streak
- TeraWulf Bets on Power Infrastructure to Lead AI Build-Out
- Amazon’s Alexa for Shopping Strengthens an Already Strong Bull Case
- Keysight: The AI and Defense Stock Seeing Big Price Target Boosts
Receive News & Ratings for Basilea Pharmaceutica Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Basilea Pharmaceutica and related companies with MarketBeat.com's FREE daily email newsletter.
